Reference number(s)
1724-H

SPECIALTY QUANTITY LIMIT PROGRAM

TASIGNA (nilotinib HCl)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the prevention/treatment of all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Tasigna (nilotinib HCl) 50 mg capsule	120 capsules per 30 days	Pediatric patients with newly diagnosed Ph+ CML-CP or resistant or intolerant Ph+ CML-CP: 230 mg/m^2 orally twice daily • rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg) Adult patients: • Newly diagnosed Ph+ CML-CP: 300 mg orally twice daily • Resistant or intolerant Ph+ CML-CP and CML-AP: 400 mg orally twice daily
Tasigna (nilotinib HCl) 150 mg capsule	120 capsules per 30 days	
Tasigna (nilotinib HCl) 200 mg capsule	120 capsules per 30 days	

*CML: chronic myeloid leukemia; CML-AP: advanced phase; CML-CP: chronic phase; Ph+: Philadelphia chromosome positive

III. REFERENCES

1. Tasigna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2018.

CVS caremark™